App-Quantinova.ai

Combining measures of immune infiltration uncovers predictors of survival in high-grade serous ovarian cancer

Anne Montfort - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

TP53

Examination of clinically relevant inhibitor selectivity in live cells across the CDK family

James Vasta - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

ASTX660, a non-peptidomimetic antagonist of cIAP1/2 and XIAP, enhances immune mediated tumor killing and induction of immunogenic cell death

Nicola Ferrari - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Fragment-based drug discovery to identify small molecule allosteric inhibitors of SHP2

Philip J. Day - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

L-Tyrosine

Reprogramming of serine metabolism during breast cancer progression

Albert Mao Li - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

A robust enhancement of cytokine production in a human chronic activation model of T cell exhaustion in vitro through blockade of PD-1/PDL-1 interactions using pembrolizumab or nivolumab; correlation with dissociated tumor immune cell responses

Omar S. Qureshi - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data

George Seed - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

A panel of NSCLC patient derived xenografts displays a distinct sensitivity profile towards checkpoint inhibitor treatment in vitro and in vivo

Robert Nunan - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

GM-CSF

Pharmacokinetics of the CDC7 inhibitor LY3143921 hydrate, a CRUK first-in-human phase I trial in patients with advanced solid tumors

Shelby Barnett - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

LY3143921

Mediators of early immune response in bronchial premalignant lesions

Carter Merenstein - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Integrating genomic and transcriptomic data to identify genetic loci associated with breast cancer risk in women of African ancestry

Guochong Jia - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

ROS dependent PGC1alpha driven mitochondrial biogenesis within the melanoma microenvironment is a pre-requisite for mitochondrial transfer from MSC to malignant cells

Prakrit Kumar - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Hydrogen peroxide

KEYNOTE-048 subgroup analysis

Barbara Burtness - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Sensitive detection of ctDNA in early stage non-small cell lung cancer patients with a personalized sequencing assay

Katrin Heider - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Frequent genomic alterations to evade the immune system in colorectal cancer with POLE gene mutation

Yoshikage Inoue - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

TP53

In vitro evaluation of platinum chemotherapy combinations with the ATR inhibitor, ceralasertib (AZD6738)

Sally E. Hall - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models

Srividya B. Balachander - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

ACP-196

Myeloma derived mitochondrial DNA activates TLR9 driven pro-tumoral expansion

Aisha Jibril - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

A bispecific antibody targeting CD28H and PDL-1 is a novel and potent immunomodulator of T cell responses

Madhu Ramaswamy - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Continuous load bearing exercise inhibits the development of prostate cancer bone metastasis

Ning Wang - American Association for Cancer Research (AACR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

N/A

Filters

45280 Abstracts